Dr. Turner on Important Steps for Genomic Profiling in Gynecologic Malignancies

Video

In Partnership With:

Taylor Turner, MD, fellow, University of Alabama at Birmingham School of Medicine, discusses important steps to implement a genomic profiling program for gynecologic malignancies.

Taylor Turner, MD, fellow, University of Alabama at Birmingham School of Medicine, discusses important steps to implement a genomic profiling program for gynecologic malignancies.

To implement a precision medicine or next-generation sequencing program, Turner says, necessary infrastructure needs to be in place. A pharmacist is needed because physicians will likely be using drugs they’ve never seen before. A dedicated individual is also needed to help interpret the results. A commercial partner will do the best they can, but they don’t normally have the expertise of a clinician in terms of various treatment options. Next, a database is needed to keep track of the rapidly evolving treatment landscape and relevant clinical trials. For example, 2 years ago, a patient with microsatellite instability-high disease didn’t have many treatment options. Now, they can receive immunotherapy.

Turner adds that this shows a lot of promise in non-ovarian malignancies.

Related Videos
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Akriti Jain, MD
Samer A. Srour, MB ChB, MS
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD
Julia Foldi, MD, PhD
Carmen Guerra, MD, MSCE, FACP
Kara N. Maxwell, MD, PhD
Abdulrahman Sinno, MD
Margaret E. Gatti-Mays, MD, MPH, FACP, of The Ohio State University Comprehensive Cancer Center
Erin K. Crane, MD, MPH